882500-21-2Relevant articles and documents
CYANOTRIAZOLE COMPOUNDS AND USES THEREOF
-
Paragraph 00288, (2020/01/11)
The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein R1, R2, R3, and R4 are as defined herein. The present invention further provides therapeutic uses of these compounds, for example against human African typanosomiasis; pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL
-
Page/Page column 173, (2016/04/09)
The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).
Quinolinone-based agonists of S1P1: Use of a N-scan SAR strategy to optimize in vitro and in vivo activity
Pennington, Lewis D.,Croghan, Michael D.,Sham, Kelvin K.C.,Pickrell, Alexander J.,Harrington, Paul E.,Frohn, Michael J.,Lanman, Brian A.,Reed, Anthony B.,Lee, Matthew R.,Xu, Han,McElvain, Michele,Xu, Yang,Zhang, Xuxia,Fiorino, Michael,Horner, Michelle,Morrison, Henry G.,Arnett, Heather A.,Fotsch, Christopher,Tasker, Andrew S.,Wong, Min,Cee, Victor J.
scheme or table, p. 527 - 531 (2012/03/26)
We reveal how a N-scan SAR strategy (systematic substitution of each CH group with a N atom) was employed for quinolinone-based S1P1 agonist 5 to modulate physicochemical properties and optimize in vitro and in vivo activity. The diaza-analog 1